ES2719840T3 - Método para detectar linfocitos B secretores de anticuerpos específicos para HLA - Google Patents

Método para detectar linfocitos B secretores de anticuerpos específicos para HLA Download PDF

Info

Publication number
ES2719840T3
ES2719840T3 ES15730984T ES15730984T ES2719840T3 ES 2719840 T3 ES2719840 T3 ES 2719840T3 ES 15730984 T ES15730984 T ES 15730984T ES 15730984 T ES15730984 T ES 15730984T ES 2719840 T3 ES2719840 T3 ES 2719840T3
Authority
ES
Spain
Prior art keywords
hla
lymphocytes
antibody
specific
secreting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15730984T
Other languages
English (en)
Spanish (es)
Inventor
Matamoros Oriol Bestard
Perrez Marc Lucia
Boira Josep Maria Grinyo
Garrit Josep Maria Cruzado
Ambros Joan Torras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL
Original Assignee
Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL filed Critical Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL
Application granted granted Critical
Publication of ES2719840T3 publication Critical patent/ES2719840T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
ES15730984T 2014-06-04 2015-06-04 Método para detectar linfocitos B secretores de anticuerpos específicos para HLA Active ES2719840T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14382214.6A EP2952893A1 (fr) 2014-06-04 2014-06-04 Procédé de détection de cellules B secrétant des anticorps spécifiques au HLA
PCT/EP2015/062517 WO2015185697A1 (fr) 2014-06-04 2015-06-04 Procédé de détection de lymphocytes b sécrétant des anticorps spécifiques pour hla

Publications (1)

Publication Number Publication Date
ES2719840T3 true ES2719840T3 (es) 2019-07-16

Family

ID=50976565

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15730984T Active ES2719840T3 (es) 2014-06-04 2015-06-04 Método para detectar linfocitos B secretores de anticuerpos específicos para HLA

Country Status (4)

Country Link
US (1) US10527630B2 (fr)
EP (2) EP2952893A1 (fr)
ES (1) ES2719840T3 (fr)
WO (1) WO2015185697A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6842195B2 (ja) * 2016-12-19 2021-03-17 国立大学法人大阪大学 インビトロでのＩｇＭ型メモリーＢ細胞分化培養系を用いた臓器移植後抗体関連型拒絶反応の早期診断法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0772619B2 (fr) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Oligonucleotides immunomodulateurs
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
JP4331944B2 (ja) 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
EP1719511B1 (fr) 2001-11-16 2008-12-10 3M Innovative Properties Company N-[4-(4-amino-2-éthyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide, composition pharmaceutique le contenant et son utilisation
WO2004071459A2 (fr) 2003-02-13 2004-08-26 3M Innovative Properties Company Procedes et compositions associes a des composes modificateurs de reponse immunitaire et recepteur 8 de type toll

Also Published As

Publication number Publication date
US20170089919A1 (en) 2017-03-30
EP3152572A1 (fr) 2017-04-12
US10527630B2 (en) 2020-01-07
WO2015185697A1 (fr) 2015-12-10
EP3152572B1 (fr) 2019-02-27
EP2952893A1 (fr) 2015-12-09

Similar Documents

Publication Publication Date Title
KR101945394B1 (ko) 관절염의 진단과 치료를 위한 14-3-3 에타 항체 및 이의 용도
US20170038396A1 (en) ELISA for a Naturally-Occurring Soluble Truncated Form of IL-23 Receptor
Wahrmann et al. Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients
JP2009034108A (ja) 治療用結合性分子
Di Niro et al. Responsive population dynamics and wide seeding into the duodenal lamina propria of transglutaminase-2-specific plasma cells in celiac disease
ES2373981T3 (es) Utilización de ant�?genos a33 y jam-it.
Kobayashi et al. Significant association between chronic antibody-mediated rejection and donor-specific antibodies against HLA-DRB rather than DQB in renal transplantation
US20100196402A1 (en) Method for Predicting the Response of a Patient to Treatment with an Anti-TNF Alpha Antibody
WO2011127543A1 (fr) Protéines qui se lient à pi16 et leurs utilisations
Crespo et al. Biomarkers to assess donor-reactive T-cell responses in kidney transplant patients
ES2719840T3 (es) Método para detectar linfocitos B secretores de anticuerpos específicos para HLA
JP2017535794A (ja) 免疫調節不全についてのマーカーとしてのｐｉｆ結合
US20070202085A1 (en) Systems and methods for monitoring immune responses and predicting outcomes in transplant recipients
KR20190104589A (ko) 진단
Callender et al. Frequency of HLA-DP-specific antibodies and a possible new cross-reacting group
Selmi et al. The etiology mystery in primary biliary cirrhosis
US20220404356A1 (en) In vitro method for determining the likelihood of occurrence of an acute microvascular rejection (amvr) against a renal allograft in an individual
Jahanbani et al. Increased macrophage phagocytic activity with TLR9 agonist conjugation of an anti-Borrelia burgdorferi monoclonal antibody
EP4246143A1 (fr) Procédé in vitro de diagnostic de pemphigus vulgaris et/ou de détermination de l'activité d'une maladie chez un patient pemphigus vulgaris
Pušnik et al. Persistent Maintenance of Atypical Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response
EP3422003A1 (fr) Procédé pour déterminer si un patient est à risque de souffrir ou de développer un cancer colorectal (crc)
WO2023217743A1 (fr) Anticorps anti-btn3a à utiliser dans des méthodes de traitement de troubles inflammatoires gastro-intestinaux
Kwan A mechanistic analysis of strategies targeting innate immunity to prevent kidney allograft rejection
Varnado Measuring Activation of the Cytosolic DNA Sensing Pathway
WO2022051816A1 (fr) Méthodes de détermination de réponse immunitaire